AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on May 29 that the global CARES Phase III clinical programme showed that treatment with anselamimab led to “nominally statistically significant and highly clinically meaningful benefit in adults with advanced kappa light chain (AL) amyloidosis as first-line therapy added to standard of care plasma cell dyscrasia (PCD) treatments, compared to placebo”. Anselamimab is a potential first-in-class anti-fibril therapy. The company added that in the overall population of patients with AL amyloidosis, treatment with anselamimab did not meet the primary endpoint, defined as “a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalisations (CVH), as previously disclosed”.
In a separate development, AstraZeneca PLC (NYSE:AZN) reported on May 28 that its Imfinzi (durvalumab), in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, received approval by the FDA in the U.S. to treat adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). Management stated that the FDA’s approval is based on positive results from the POTOMAC Phase III trial.
AstraZeneca PLC (NYSE:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NYSE:AZN) distributes its products and services through local representative offices and distributors.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Chicago, Illinois-based Mondelez International, Inc (MDLZ) manufactures, markets, and sells snack food and beverage products. Valued at $78.4 billion by market cap, the company offers a wide range of products such as biscuits, baked snacks, chocolates, gums, candies, cheese, and powdered beverages under brands like Oreo, Ritz, LU, CLIF Bar, Tate’s Bake Shop, Cadbury Dairy Milk, Milka, and Toblerone.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and MDLZ perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the confectioners industry.
Dear Microsoft Stock Fans, Mark Your Calendars for June 2
Microsoft Stock Is Up Nearly 30% From Its March Lows, But You Shouldn’t Sell MSFT Just Yet
Dell Stock Could Be Worth 30% More - Based on Strong AI Demand and FCF

Updated June 3, 2026 1:45 pm ET
Listen
(48 sec)
Front Month Comex Gold for June delivery lost $52.40 per troy ounce, or 1.17% to $4436.70 today
—Down two of the past three sessions

Victoria's Secret & Co. (NYSE:VSCO) reported much stronger-than-expected first quarter results, with earnings and revenue topping Wall Street estimates and the company raising its full-year outlook.
Shares surged as much as 50% following the report, briefly trading above $80 per share.
The company reported net sales of $1.56 billion for the quarter, up 15.3% year-over-year and ahead of **** yst expectations of about $1.52 billion. Comparable sales rose 13% compared with the prior year period.
Adjusted earnings per share came in at $0.60, significantly above the $0.29 to $0.32 range expected by **** ysts. On a reported basis, net income was $48 million, or $0.56 per diluted share, compared with a net loss of $2 million in the same quarter last year.
Operating income rose to $76 million from $20 million a year earlier. On an adjusted basis, operating income reached $80 million, above the company’s prior guidance range of $32 million to $42 million.

By Amanda Cooper
LONDON, June 2 (Reuters) - Global stocks rallied on Tuesday, buoyed by fresh AI optimism after Anthropic moved towards a U.S. stock market listing, while oil prices and bond yields fell on renewed hopes of ‌a U.S.-Iran deal.
Brent crude futures dropped more than 1% below $94 a barrel, paring the previous session's sharp gains, after ‌U.S. President Donald Trump said talks with Iran continued.
His comments came despite a report that Tehran had suspended indirect negotiations with Washington to end hostilities, keeping investors cautious about efforts to end the three-month war and underlining the fragility of an ongoing ceasefire.
Europe's STOXX 600 was up 0.7% by midday, as a strong forecast from chipmaker STMicroelectronics lifted technology stocks.